ASP ISOTOPES INC - ASP Isotopes Inc. announces receipt of regulatory approvals for acquisition of Renergen Limited

ASP Isotopes Inc. announces receipt of regulatory approvals for acquisition of Renergen Limited

ASP ISOTOPES INC.
(Incorporated in the State of Delaware,
United States of America)
(Delaware file number 6228898)
Ticker Symbol: NASDAQ: ASPI
ISIN: US00218A1051
LEI: 6488WHV94BZ496OZ3219
JSE Share Code: ISO
("ASPI" or "the Company")



ASP Isotopes Inc. Announces Receipt of Regulatory Approvals for Acquisition of Renergen
Limited


Positive progress in operations at Renergen's Virginia Gas Project with a production update
expected at the end of January 2026.

Washington, D.C., December 17, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP
Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology
and processes for the production of isotopes for use in multiple industries, today announced that all required
regulatory approvals and clearances have been obtained for ASP Isotopes' proposed offer to acquire all of
the issued ordinary shares of JSE-listed Renergen Limited ("Renergen"), pursuant to a scheme of
arrangement under South African law pursuant to which Renergen shareholders will receive 0.09196 new
ASP Isotopes shares for each Renergen share held on the record date (the "Scheme").

Accordingly, all remaining conditions precedent have been fulfilled or, where applicable, waived and the
Scheme has become unconditional. Implementation of the Scheme will begin once the South African
Takeover Regulation Panel issues the requisite compliance certificate, which is anticipated to be received
on or about December 18, 2025. Upon receipt of the compliance certificate, ASP Isotopes and Renergen
will publish the finalization announcement, containing the remaining salient dates and times for
implementation of the Scheme.

Renergen is a public company incorporated under the laws of the Republic of South Africa, focused on
production of liquefied helium (LHe) and liquefied natural gas (LNG) and is funded by the United States
government given helium's strategic significance. The combination of Renergen and ASP Isotopes aims
to create a global leader in the production of critical and strategically important materials, including
electronic gases such as helium, various fluorinated products and isotopically enriched gases. The
combination is expected to create a vertically and horizontally integrated supply chain with significant
geographic and customer overlap with substantial synergies expected from 2026.

ASP Isotopes has been advised of positive progress in operations at Renergen's Virginia Gas Project and
expects to provide a production update at the end of January 2026 following implementation of the Scheme.

About ASP Isotopes Inc.

ASP Isotopes Inc. is a development stage advanced materials company dedicated to the development of
technology and processes to produce isotopes for use in multiple industries. The Company employs
proprietary technology, the Aerodynamic Separation Process ("ASP technology"). The Company's initial
focus is on producing and commercializing highly enriched isotopes for the healthcare and technology
industries. The Company also plans to enrich isotopes for the nuclear energy sector using Quantum
Enrichment technology that the Company is developing. The Company has isotope enrichment facilities in
Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light
isotopes).

There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and
Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare
applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. We believe
the ASP technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass
molecules. For more information, please visit www.aspisotopes.com.

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of the safe harbor provisions
of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead, they are based only on our current beliefs,
expectations, and assumptions regarding the future of our business, future plans and strategies,
projections, anticipated events and trends, the economy, and other future conditions. Forward-looking
statements can be identified by words such as "goal", "target", "believes," "plans," "anticipates," "expects,"
"aims", "intends", "estimates," "projects," "will," "may," "might," "seeks", "sees", "should," "would," "expect,"
"positioned," "strategy," and words of a similar nature. Examples of forward-looking statements include,
among others but are not limited to, statements relating to the completion of the transactions in the
anticipated timeframe or at all, the subsequent integration of ASP Isotopes's and Renergen's businesses
and the ability to recognize the anticipated synergies and benefits of the transactions, the access to
available financing (including financing in connection with the transactions) on a timely basis and on
reasonable terms, the plans for a listing of Quantum Leap Energy as a standalone public company, the
anticipated market demand for future products of ASP Isotopes and Renergen, the future of the company's
enrichment technologies as applied to uranium enrichment, the outcome of the company's initiative to
commence enrichment of uranium in South Africa and the company's discussions with nuclear regulators,
and statements we make regarding expected operating results, such as future revenues and prospects
from the potential commercialization of isotopes, future performance under contracts, and our strategies for
product development, engaging with potential customers, market position, and financial results. Because
forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and
changes in circumstances that are difficult to predict, many of which are outside our control. Our actual
results, financial condition, and events may differ materially from those indicated in the forward-looking
statements based upon a number of factors. Forward-looking statements are not a guarantee of future
performance or developments. You are strongly cautioned that reliance on any forward-looking statements
involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these
forward-looking statements. There are many important factors that could cause our actual results and
financial condition to differ materially from those indicated in the forward-looking statements, including, but
not limited to, risks related to: (i) the implementation of the Scheme in the anticipated timeframe or at all;
(ii) the satisfaction of the Scheme conditions; (iii) the failure to obtain necessary regulatory approvals and
third party consents; (iv) the ability to realize the anticipated benefits of the proposed acquisition of
Renergen; (v) the ability to successfully integrate the businesses; (vi) disruption from the proposed
acquisition of Renergen making it more difficult to maintain business and operational relationships; (vii) the
negative effects of this announcement or the consummation of the proposed acquisition of Renergen on
the market price of Renergen's or ASPI's securities; (viii) significant transaction costs and unknown
liabilities; (ix) litigation or regulatory actions related to the proposed acquisition of Renergen; and (x) and
the factors disclosed in Part I, Item 1A. "Risk Factors" of the company's Annual Report on Form 10-K for
the fiscal year ended December 31, 2024 and any amendments thereto and in the company's subsequent
reports and filings with the U.S. Securities and Exchange Commission. Any forward-looking statement
made by us in this press release is based only on information currently available to us and speaks only as
of the date on which it is made. We undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future developments or otherwise. No information in this
press release should be interpreted as an indication of future success, revenues, results of operation, or
stock price. All forward-looking statements herein are qualified by reference to the cautionary statements
set forth herein and should not be relied upon.

Contacts

Jason Assad– Investor relations
Email: Jassad@aspisotopes.com

The Company has a primary listing on the Nasdaq and a secondary listing on the Main Board of the JSE.

17 December 2025

Sponsor
Valeo Capital Proprietary Limited

Date: 17-12-2025 04:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.